Back to companies

Intra-Cellular Therapies Inc: Overview

Intra-Cellular Therapies Inc (ICTI) carries out the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company develops drugs for the treatment of heart failure, immune system regulation, neurodegenerative diseases, cancers and other non-CNS disorders. Its pipeline products include lumateperone (ITI-007) which is used for the treatment of schizophrenia, behavioral disturbances associated with dementia and Alzheimer's disease, bipolar disorder and behavioral disturbances such as dementia and Alzheimer's disease. ICTI is headquartered in New York City, New York, the US.

Headquarters United States of America

Address 430 East 29th Street, New York, 10016


Telephone 1 212 9233344

No of Employees 512

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange ITCI (NASD)

Revenue (2021) $83.8M 267.3% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -25.2% (2021 vs 2020)

Market Cap* $4.5B

Net Profit Margin (2021) XXX 65.9% (2021 vs 2020)

* As of and is in US$

Access premium data and analytics for Intra-Cellular Therapies Inc

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Intra-Cellular Therapies Inc’s relevant decision makers and contact details.

40+

Clinical Trials

Determine Intra-Cellular Therapies Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

16+

Pipeline Drugs

Identify which of Intra-Cellular Therapies Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

6

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Intra-Cellular Therapies Inc’s commercialized product portfolio to stay one step ahead of the market.

20+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Intra-Cellular Therapies Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Technologies: CNSProfile
CNSProfile Platform
Phosphodiesterase (PDE) Platform
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 Regulatory Approval In December, the company announced U.S. Food and Drug Administration (FDA) approved CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults.
2015 Research and Development In September, Intra-Cellular Therapies, Inc. identified a higher dose of its lead drug ITI-007 helps in reducing the severity of schizophrenia symptoms.
2014 Contracts/Agreements In November, Intra-Cellular Therapies and Takeda has mutually terminated their collaboration to develop Phosphodiesterase (PDE1) Inhibitors for CNS Disorders.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Intra-Cellular Therapies Inc Supernus Pharmaceuticals Inc Concert Pharmaceuticals Inc Axsome Therapeutics Inc Intellect Neurosciences Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City New York Rockville Lexington New York Englewood Cliffs
State/Province New York Maryland Massachusetts New York New Jersey
No. of Employees 512 575 64 108 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Sharon Mates Chief Executive Officer; President; Chairman Executive Board 2002 69
Lawrence J. Hineline Chief Financial Officer; Senior Vice President - Finance; Treasurer Senior Management 2013 64
Karen Patruno Sheehy Senior Vice President; Chief Compliance Officer Senior Management 2019 -
Suresh Durgam Senior Vice President; Chief Medical Officer Senior Management 2020 53
Robert E. Davis Chief Scientific Officer; Senior Vice President Senior Management 2015 69
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer